Baillie Gifford & Co’s Intersect ENT, Inc XENT Stock Holding History

Baillie Gifford & Co’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-440	Closed	-$12K	–	522
2022 Q1	$12K	Hold	440	–	–	﹤0.01%	425
2021 Q4	$12K	Hold	440	–	–	﹤0.01%	434
2021 Q3	$12K	Buy	440 +79	+22%	+$1.95K	﹤0.01%	439
2021 Q2	$6K	Hold	361	–	–	﹤0.01%	459
2021 Q1	$8K	Buy	361 +21	+6%	+$485	﹤0.01%	423
2020 Q4	$8K	Buy	+340	New	+$6.47K	﹤0.01%	401

Baillie Gifford & Co's XENT Position: Q2 2022 in Review

Baillie Gifford & Co sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 440 shares — an estimated $12K sold.

Baillie Gifford & Co first reported a position in XENT in Q4 2020 and held it in 6 quarters. The position peaked at $12K in Q1 2022. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

Baillie Gifford & Co reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
Baillie Gifford & Co sold 440 Intersect ENT, Inc shares in Q2 2022, an estimated $12K.
Baillie Gifford & Co first reported a position in Intersect ENT, Inc in Q4 2020 and held it in 6 quarters.
Baillie Gifford & Co's Intersect ENT, Inc position peaked at $12K in Q1 2022.
0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on Baillie Gifford & Co's 13F filing for Q2 2022, filed 8 Aug 2022.